ClinicalTrials.gg
WithdrawnNCT04542434Updated Feb 21, 2022

Niclosamide in COVID-19

A Phase 2 interventional study of Niclosamide Oral Tablet and Placebo in Covid19, sponsored by Entero Therapeutics. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-21.

Sponsored by Entero Therapeutics · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Sponsor asset acquired by another pharma company who opened their own IND for this compound. First Wave Bio never started this study in the US or ex-US.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a two-part, Phase 2, multicentre, randomized, double blind, 2-arm placebo-controlled study in adults with moderate COVID-19 with gastrointestinal signs and symptoms

02

Conditions studied

  • Covid19

Browse trials for

03

In context

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Lead sponsor

Entero Therapeutics is the lead sponsor of 10 studies on the registry; none are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Part 1 only: Patients hospitalized with a primary diagnosis of COVID-19 with or without pneumonia, who are expected to remain in hospital at least seven days after the randomization and who accept continuing to be assessed for the study procedures (home or outpatient unit) up to 6 weeks in case of discharge.

Part 2 only: Patients with a primary diagnosis of COVID-19 with or without pneumonia who are not planned to be hospitalized.

  • Patients who prior to developing COVID-19 usually have normal bowel habits defined as at least solid-formed 3 stools per week and no more than 3 solid-formed stools per day.
  • SARS-CoV-2 RNA presence in rectal swab (or stool test) ≤2 days before randomization by local or central lab.
  • Diarrhea defined as at least 3 watery stools in the last 24 hours prior to enrolment

Exclusion criteria

Exclusion Criteria:

  • At the time of randomization patients requiring ICU admission or patients with severe respiratory insufficiency requiring mechanical ventilation or with rapid worsening of respiratory function leading to expectation for mechanical ventilation or ICU admission.
  • Evidence of rapid clinical deterioration or existence of any life-threatening co-morbidity or any other medical condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Niclosamide

    Drug: Niclosamide Oral Tablet

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Niclosamide tablets 400 mg 3 times daily for 14 days

  • DrugPlacebo

    Matching placebo tablets 3 times daily for 14 days

06

What researchers measure

Primary outcomes

  1. Mortality

    All-cause mortality

    Time frame: From Day 1 to 6 weeks

  2. TEAE

    Proportion of patients with Treatment Emergent Adverse Events (TEAE) leading to study drug discontinuation

    Time frame: From Day 1 to 6 weeks

  3. SAEs

    Serious adverse event (SAE) coded by System Organ Class (SOC) and Preferred Term (PT), using the Medical Dictionary for Regulatory Activities (MedDRA)

    Time frame: From Day 1 to end of study

  4. Safety laboratory

    Change in safety laboratory tests from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided

    Time frame: From Day 1 to 6 weeks

  5. Blood pressure

    Change in sitting systolic and diastolic blood pressure from baseline to 6 weeks summarized descriptively by visit and presented as shift tables

    Time frame: From Day 1 to 6 weeks

  6. fecal RNA virus clearance

    time to fecal RNA virus clearance (rectal swab or stool sample) assessed by RT-qPCR in the niclosamide group, compared to the placebo group (Part 2 only)

    Time frame: From Day 1 to 6 weeks

  7. Body temperature

    Change in body temperature from baseline to 6 weeks summarized descriptively by visit and presented as shift tables

    Time frame: From Day 1 to 6 weeks

  8. Heart rate

    Change in heart rate from baseline to 6 weeks summarized descriptively by visit and presented as shift tables

    Time frame: From Day 1 to 6 weeks

  9. SaO2

    Change in SaO2 from baseline to 6 weeks summarized descriptively by visit and presented as shift tables

    Time frame: From Day 1 to 6 weeks

  10. ECG

    Change in ECG parameters including: 1. PR interval 2. RR interval 3. QRS interval 4 QT interval 5. HR interval 6. QtcF interval. All intervals summarized descriptively by visit from baseline to 6 weeks

    Time frame: From Day 1 to 6 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Jan 2022, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2020
First posted
Sep 9, 2020
StartActual
Jan 20, 2022
Primary completionActual
Jan 20, 2022
CompletionActual
Jan 20, 2022
Last update
Feb 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04542434
Lead sponsor
Entero Therapeutics
Responsible party
Sponsor
First posted
Sep 9, 2020
Start date
Jan 20, 2022
Primary completion
Jan 20, 2022
Completion
Jan 20, 2022
Last update
Feb 21, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Niclosamide

Start the discussion